△ 2024.12月訊聯生技以Exosome Foundry主題參與醫療科技展
外泌體保養品正引領全球美容市場新浪潮，國際精品相繼推出仿生外泌體保養妝品，光電雷射領導品牌LUMENIS也推出《心動1565外泌體》面膜+精華液，結合外泌體與高保濕修護成分，幫助縮短醫美療程恢復期。
訊聯生技憑藉25年的深厚再生醫學研發實力，2002年即投入外泌體研發技術，2024年更整合旗下訊聯細胞智藥、AI智慧研發團隊、多種來源的外泌體研發技術，以AI Exosome Foundry平台創新服務，透過AI篩選、純化外泌體到設計製程，為客戶提供妝品原料調配、客製化代工與新品開發的一站式服務。
△ 光電雷射領導品牌LUMENIS也推出《心動1565外泌體》面膜+精華液
訊聯開創跨18業態應用，包括中草藥、動物、婦產科、光電雷射等，成功推向國際市場，為全球生技與美容產業帶來創新突破。海外進展包括：
1.在東北亞市場，訊聯外泌體原料打進全球妝品出口排名第四、K-Beauty重鎮韓國，為當地醫療器材商製成醫學美容皮膚促進劑(cosmetics skin booster)，並取得韓國食藥部(MFDS)化妝品類別登記，於市場銷售。
2.訊聯外泌體製品已取得馬來西亞國家藥品管理局(NPRA)妝品註冊許可，搶進皮膚、毛髮、慢性傷口等健康保健市場；更以外泌體原料研發代工Exosome Foundry服務，結盟馬來西亞業者並透過在地銷售網路，擴大提供高品質的產品與服務。
3.訊聯外泌體透過拉丁美洲最著名的醫美器材與保養品代理商進行產品登記，打進哥倫比亞醫療通路，透過實體及線上網絡雙軌並進，並與南美洲擁有大量粉絲的KOL強強聯手，進一步擴大至拉丁美洲鄰近各國醫美市場。
訊聯獲准《特管辦法》核可計畫已達63項，再生醫學類脂肪幹細胞獲准件數最多；訊聯接受癌症免疫細胞治療CIK委託製備，除了實體癌第4期之外，實體癌第1~3期/經標準治療無效的細胞治療計畫，也獲核可製備。
BIONET Corp. AI Enhances Exosome Technology, Expanding into Korea, Malaysia, and Latin America’s Aesthetic Markets
Exosome-based skincare is driving a new wave in the global beauty market, with luxury brands launching biomimetic exosome cosmetic products. Lumenis, a leader in laser and energy-based treatments, has also introduced the "Heartbeat 1565 Exosome" mask and serum, combining exosomes with advanced hydrating and reparative ingredients to shorten post-procedure recovery time.
Leveraging 25 years of expertise in regenerative medicine, BIONET Corp. has been at the forefront of exosome research since 2002. In 2024, the company integrated its BIONET Cell Intelligent Biopharma, AI-driven R&D team, and multi-source exosome technology to launch the AI Exosome Foundry platform. This innovative platform utilizes AI to screen, purify, and optimize exosome production, providing formulation services, custom manufacturing, and new product development for the beauty and biotech industries.
Global Expansion Across 18 Industry Sectors
BIONET has successfully pioneered exosome applications across 18 industries, including herbal medicine, veterinary science, obstetrics & gynecology, and laser aesthetics, making significant strides in international markets.
Key Global Milestones
★ Korea: BIONET’s exosome ingredients have entered Korea, the fourth-largest cosmetic exporter globally and a hub of K-Beauty innovation. The company collaborates with local medical device firms to develop cosmetic skin boosters and has secured registration with Korea’s Ministry of Food and Drug Safety (MFDS) for commercialization.
★ Malaysia: BIONET has obtained cosmetic product registration approval from Malaysia’s National Pharmaceutical Regulatory Agency (NPRA). The company is expanding into skincare, hair care, and chronic wound healing markets while partnering with local businesses via its Exosome Foundry platform to develop and distribute high-quality exosome-based products.
★ Latin America: BIONET has entered Colombia’s medical aesthetic market through one of Latin America’s top aesthetic device and skincare distributors. The company is leveraging both physical and online sales channels, collaborating with popular South American KOLs, and expanding its reach across the region.
Pioneering Regenerative Medicine & Cell Therapy
BIONET leads Taiwan in Special Regulations for Cell Therapy approvals, with 63 projects cleared, making it the top provider of adipose-derived stem cell therapies. The company also offers Cancer Immunotherapy (CIK) cell processing services, now extending beyond stage IV solid tumors to include stages I-III cases and patients unresponsive to standard treatments.
